Abstract

Medical decision-making is revolutionizing with the introduction of artificial intelligence and machine learning. Yet, traditional algorithms using biomarkers to optimize drug treatment continue to be important and necessary. In this context, early diagnosis and rational antimicrobial therapy of sepsis and lower respiratory tract infections (LRTI) are vital to prevent morbidity and mortality. In this study we report an original cost-effectiveness analysis (CEA) of using a procalcitonin (PCT)-based decision algorithm to guide antibiotic prescription for hospitalized sepsis and LRTI patients versus standard care. We conducted a CEA using a decision-tree model before and after the implementation of PCT-guided antibiotic stewardship (ABS) using real-world U.S. hospital-specific data. The CEA included societal and hospital perspectives with the time horizon covering the length of hospital stay. The main outcomes were average total costs per patient, and numbers of patients with Clostridium difficile and antibiotic resistance (ABR) infections. We found that health care with the PCT decision algorithm for hospitalized sepsis and LRTI patients resulted in shorter length of stay, reduced antibiotic use, fewer mechanical ventilation days, and lower numbers of patients with C. difficile and ABR infections. The PCT-guided health care resulted in cost savings of $25,611 (49% reduction from standard care) for sepsis and $3630 (23% reduction) for LRTI, on average per patient. In conclusion, the PCT decision algorithm for ABS in sepsis and LRTI might offer cost savings in comparison with standard care in a U.S. hospital context. To the best of our knowledge, this is the first health economic analysis on PCT implementation using U.S. real-world data. We suggest that future CEA studies in other U.S. and worldwide settings are warranted in the current age when PCT and other decision algorithms are increasingly deployed in precision therapeutics and evidence-based medicine.

Highlights

  • Sepsis and lower respiratory tract infections (LRTI) cause morbidity and mortality among hospitalized patients (Dellinger et al, 2013)

  • In this study we report an original cost-effectiveness analysis (CEA) of using a procalcitonin (PCT)-based decision algorithm to guide antibiotic prescription for hospitalized sepsis and LRTI patients versus standard care

  • We found that health care with the PCT decision algorithm for hospitalized sepsis and LRTI patients resulted in shorter length of stay, reduced antibiotic use, fewer mechanical ventilation days, and lower numbers of patients with C. difficile and antibiotic resistance (ABR) infections

Read more

Summary

Introduction

Sepsis and lower respiratory tract infections (LRTI) cause morbidity and mortality among hospitalized patients (Dellinger et al, 2013). Overprescribing antibiotics can contribute to antibiotic resistance (ABR) and Clostridium difficile infections (CDI) (Schuetz et al, 2011; Wenzel and Edmond, 2000). Guidance on when to initiate or terminate antibiotic therapy could aid reducing the overuse of antibiotics, and thereby reduce ABR and the number of CDI patients. Procalcitonin (PCT) is a biomarker that is able to provide guidance in clinical decision-making on antibiotic usage (Schuetz et al, 2015). Within 3–4 h after onset of an inflammatory response PCT is elevated, after which it peaks at 14–25 h. With a half-life of *24 h, PCT decreases rapidly when the inflammatory response begins to resolve (Linscheid et al, 2003; Muller et al, 2001). PCT values can support clinical decision-making on antibiotic initiation and discontinuation

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call